BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16700817)

  • 1. Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations.
    Barbosa F; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):559-64. PubMed ID: 16700817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting effects of age on the plasma/whole blood lead ratio in men and women with a history of lead exposure.
    Barbosa F; Ramires I; Rodrigues MH; Saint' Pierre TD; Curtius AJ; Buzalaf MR; Gerlach RF; Tanus-Santos JE
    Environ Res; 2006 Sep; 102(1):90-5. PubMed ID: 16678152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence for lead-induced inhibition of nitric oxide formation.
    Barbosa F; Sertorio JT; Gerlach RF; Tanus-Santos JE
    Arch Toxicol; 2006 Dec; 80(12):811-6. PubMed ID: 16670857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury.
    Jacob-Ferreira AL; Passos CJ; Gerlach RF; Barbosa F; Tanus-Santos JE
    Sci Total Environ; 2010 Sep; 408(19):4085-92. PubMed ID: 20554312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Jacob-Ferreira AL; Passos CJ; Jordão AA; Fillion M; Mergler D; Lemire M; Gerlach RF; Barbosa F; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):281-8. PubMed ID: 19594729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury.
    Jacob-Ferreira AL; Lacchini R; Gerlach RF; Passos CJ; Barbosa F; Tanus-Santos JE
    Sci Total Environ; 2011 Sep; 409(20):4242-6. PubMed ID: 21794897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
    Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
    Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers.
    Demacq C; Metzger IF; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2008 Aug; 394(1-2):72-6. PubMed ID: 18455513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
    Gerlach RF; Demacq C; Jung K; Tanus-Santos JE
    Clin Biochem; 2007 Jan; 40(1-2):119-23. PubMed ID: 17150202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the use of salivary lead levels as a surrogate of blood lead or plasma lead levels in lead exposed subjects.
    Barbosa F; Corrêa Rodrigues MH; Buzalaf MR; Krug FJ; Gerlach RF; Tanus-Santos JE
    Arch Toxicol; 2006 Oct; 80(10):633-7. PubMed ID: 16614825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Field screening of blood lead levels in remote Andean villages.
    Counter SA; Buchanan LH; Laurell G; Ortega F
    Neurotoxicology; 1998 Dec; 19(6):871-7. PubMed ID: 9863775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio.
    Montenegro MF; Barbosa F; Sandrim VC; Gerlach RF; Tanus-Santos JE
    Arch Toxicol; 2006 Jul; 80(7):394-8. PubMed ID: 16341691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.